We have studied the contribution of platelets to the coagulation of plasma and the effects of activation or inhibition of platelets on the coagulation process in unanticoagulated fresh whole blood (subsequently termed native blood). For this purpose we have used a free oscillating rheometer (FOR), the ReoRox4  , a new instrument enabling non-invasive viscoelastic measurements of clot formation in plasma and whole blood.
Introduction
The fact that blood cells affect the coagulation process has long been known. Already in 1905 Morawitz reported that cell-free plasma did not coagulate if stored in paraffinlined containers [1] . It is also known that patients with severe thrombocytopenia (<5  10 9 /L) frequently experience serious bleeding episodes [2] . However, few laboratory tests of coagulation measure the contribution of platelets to clotting even though they are known to participate in all phases of hemostasis in vivo. Besides their role in platelet plug formation, they provide the surface on which the tenase and prothrombinase complexes form (for reviews see references [3, 4] ). This entails the translocation of negatively charged phosphatidylserine (PS) residues to the platelet surface. Furthermore, platelets from healthy donors differ in their ability to support activation of factor Xa and thrombin, a difference not correlated to translocation of phosphatidylserine [5] , thus indicating existence of additional platelet features important for assembly of these complexes. Another such example is the Stormorken syndrome, a disorder with spontaneous platelet exposure of PS [6] , which is characterised by bleeding but no increase in thrombin formation [7] .
Even though the tissue factor-factor VIIa complex is the initial physiological activator of factor X, the Xa so derived can not substitute for factor Xa formed by the tenase complex on the platelet surface since it is largely inactivated before it reaches the platelet surface [8] . This implies that normal amplification of the humoral coagulation cascade is critically dependent on normal platelet structure and activation.
Platelet surface receptors are also critical for platelet adhesion and aggregation. Binding of platelets to subendothelial structures at high shear stress is primarily mediated by interactions of the GPIb receptor and von Willebrand factor (vWF) [9] . Platelet 31/10/2011 activation also induces a conformational change in the GPIIb/IIIa complex, making it able to bind vWF and fibrinogen, thereby strengthening the clot and inducing platelet aggregation [10] . GPIIb/IIIa antagonists have been used successfully to prevent rethrombosis after coronary angioplasty and are of benefit in the treatment of acute coronary syndromes [11] . In addition, studies with GPIIb/IIIa antagonists suggest that this receptor is important for PS exposure and factor V binding to activated platelets [12] .
In this work we have studied the contribution of platelets to the coagulation of plasma and to unanticoagulated fresh whole blood (native blood). For these studies we used a newly developed free oscillating rheometer (FOR), the ReoRox4  [13] . We have previously used this instrument in our laboratory to study the effect of adding endothelial cells to plasma in patients with thrombosis [14] .
Materials and methods

Instruments and reagents
Four channel free oscillation rheometers (FOR), ReoRox4  , disposable polypropylene sample cups (prod. no. GHI 205) and softwares (ReoRox4  v2.00 and ReoRox4  Viewer v1.03, 2.0, 2.01) were obtained from GHI (Global Haemostasis Institute AB), Linköping, Sweden. In this instrument the cup containing the sample is placed on the sample cup holder, which is attached to the foundation by a perpendicular torsion wire This state detector algorithm was set to high sensitivity in all experiments described here, and the related endpoint is referred to as "clotting time". To study further changes in the forming coagulum, the time for the frequency minimum (here referred to as for 24 hours to examine the stability of plasma factors. APTT and PT were measured on aliquots of the sample after addition of 0.129 mol/L sodium citrate in a sample-to-citrate ratio of 10:1. This was done immediately after plasma preparation and after 24 hours storage. D-dimer levels were also measured in samples stored for two months at room temperature (n=4) or at 37C (n=6).
Effects of platelet agonists on coagulation
Native blood was collected in empty plastic vacuum tubes. The final volume was 300 L.
Clotting times were determined with the rheometer software. Duplicate PRP samples from 8 individuals were analysed.
Effects of platelet GPIIb/IIIa antagonists on coagulation
Blood was collected in empty plastic vacuum tubes. Within 5 minutes of collection, 250
L of blood was transferred to a sample cup containing 25 L of SFLLRN (60 g/mL) or collagen (3.3 g/mL) and 25 L of HEPES buffer or a GPIIb/IIIa antagonist, MK-852
(43 g/mL) or abciximab (3 L 2 mg/mL + 22 L buffer). The fibrinogen binding in the presence of these antagonist concentrations was shown be less than the binding of a control antibody in a flow cytometric assay [18] .
Clotting times were determined by the instrument's software program. The frequency minimum and clot completion times were determined graphically from the curves. All samples were analysed in duplicate.
Statistics
Data analysis was performed using Statistica for Windows (StatSoft, Inc, Tulsa, USA). Comparisons between groups were made with the non-parametric Wilcoxon
Matched Pairs test.
Results
Cell free plasma without anticoagulant
Cell free plasma with no anticoagulant, prepared as described, did not coagulate, even This fibrin network dissolved with time and was not visible after two month's storage.
D-dimer levels were high after storage for two months at room temperature (294.00  64.63 mg/L, n=4). Samples stored at 37C showed much lower levels (3.43  2.98 mg/L, n=6) (p< 0.01), indicating that these samples had not been coagulated during storage.
Effects of platelet agonists on clotting time
Addition of SFLLRN or collagen to native blood samples shortened the clotting time by over 40% as compared to untreated whole blood (p=0.018 for SFLLRN, p<0.01 for collagen). Results are shown in figure 2. To investigate whether the effects were caused by platelet activation, the same experiments were performed with citrated platelet-rich plasma (PRP). Results are shown in figure 3 . Both collagen and SFLLRN addition decreased the clotting time by 50% (p=0.012).
Effects of platelet agonists and GPIIb/IIIa antagonists on coagulation
Rheometer tracings of whole blood coagulation in the presence and absence of platelet agonists were distinctly different. Samples without platelet agonists often showed a small, broad peak in logarithmic damping accompanied by a slow decrease in frequency, 
Discussion
It is obvious that platelets are important in several aspects of the coagulation process.
We showed in this study that in plasma contacted by a low-activating surface, a rapid removal of all cells was enough to keep the plasma anticoagulated. Stimulation of platelets via the thrombin receptor (with SFLLRN) or the collagen receptor shortened the clotting time for native whole blood, indicating an important role for the platelet in the amplification of the coagulation process. The same results were also obtained in platelet rich plasma, indicating that no other blood cell is responsible for this effect.
Normally, the clot retracted from the wall of the sample cup after clot formation. In samples with GPIIb/IIIa inhibitors, however, no clot retraction was seen, corresponding to the situation in patients with Glanzmann thrombastenia [19] .
The experiments with the GPIIb/IIIa antagonists MK-852 and abciximab indicate that important differences exists in the action of these two inhibitors, but that that this difference only shows when collagen is used as platelet agonist. This is in accordance with earlier reports about an increased procoagulant activity in platelets stimulated with collagen and thrombin in the presence of MK-852, but not with thrombin as single stimulus [20] .
The activating effect of MK-852 in collagen stimulated samples was only affecting the early stages of clotting. The late phase of coagulation was prolonged as compared to collagen, just as in the samples with abciximab. In another study measuring only thrombin generation, the increase in thrombin generation with some GPIIb/IIIa antagonists was observed for all measured time points [21] . Some factors apart from the rate of thrombin generation therefore seem to affect the coagulum formed in the rheometer. One possible explanation is that the late phase is much dependent on forces 31/10/2011 exerted by retracting platelets integrated in the fibrin network. In the presence of GPIIb/IIIa receptor antagonists, the integration of platelets are likely to be compromised whereby the effects of platelet retraction on the clot are diminished.
GPIIb/IIIa has been shown to bind prothrombin and to accelerate its conversion to thrombin [22] . GPIIb/IIIa antagonists have been shown to decrease both prothrombinase and tenase activity and PS exposure by thrombin stimulated platelets [23, 24] , and to decrease the binding of factor V and the exposure of PS by activated platelets in a whole blood assay [12] , but the efficiency varied between different antagonists. The addition of abciximab has been reported to decrease the thrombin generation by 25-30% [21] . This could explain the prolonged clotting times observed in our experiments. By contrast, addition of MK-852 to collagen appears to enhance the procoagulant properties of the platelet. MK-852 interferes with the RGD binding site of the GPIIb/IIIa receptor [25] , just like the oral substances shown to display an even increased mortality in clinical trials in a recent meta-analysis [26] .
The ability to detect changes in whole blood samples due to the treatment with platelet antagonists opens interesting possibilities in the diagnostic area. FOR analysis of patient samples could be used to monitor the effects of treatment with e.g. abciximab, without disturbing effects of citrate in the samples. This instrument measures the combined effect of these drugs, including both anti-and procoagulant effects. It has earlier been reported that citrate seems to enhance the potency of some GPIIb/IIIa antagonists [27] , implicating that the analysis of citrated samples is unsuitable for the prediction of their efficiency in vivo. added. Asterisks show significant differences as compared to the samples with collagen alone from the same donor (*= p<0.05, **=p<0.01).
